Decreased Serum Total Cholesterol Research Articles

Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon-alfa.

There is no satisfactory standard for predicting HBeAg seroconversion during Pegylated interferon alpha (PegIFNα) treatment. Studies have shown that IFNα therapy in chronic hepatitis C patients could alter serum lipid profiles. However, there have been no studies on lipid changes that predict the outcome of PegIFNα monotherapy in treated-naive chronic hepatitis B (CHB) patients. This retrospective study included 130 treated-naive HBeAg-positive CHB patients receiving PegIFNα monotherapy. The relationship between serum lipid changes and HBeAg seroconversion was analysed. The TC-ALT-HBsAg-HBeAg-Genotype-Age (CASEGA) model was established to predict HBeAg seroconversion after PegIFN-α monotherapy. Among 130 patients, 33 achieved HBeAg seroconversion (SR) and 97 did not achieve HBeAg seroconversion (NR). The decrease in serum total cholesterol (TC) in the NR group was significantly higher than in the SR group at Week 24 (-9.59% vs. -0.31%, p< 0.001). Multivariate logistic regression analysis showed that the change in TC at Week 24 (odds ratio=1.065, p= 0.009) was an independent predictor of HBeAg seroconversion. The area under the receiver operating characteristic curve for the CASEGA model was 0.883. The model score at the maximum Youden index was 90, and the specificity, sensitivity, positive predictive value and negative predictive value were 0.727, 0.794, 0.546 and 0.895, respectively. The HBeAg seroconversion rate at Week 72 in patients with scores >90 was significantly higher than that in patients with scores <90 (54.55% vs. 10.47%, p< 0.001). This study indicated that the change in the TC level at 24 weeks in CHB patients treated with PegIFNα was associated with HBeAg seroconversion. The CASEGA prediction model based on the TC change rate of 24 weeks has good predictive efficiency for HBeAg seroconversion.

Evaluation of Caralluma edulis for its Potential Against Obesity, Atherosclerosis and Hypertension.

Obesity, a chronic metabolic condition, is an increase in fat mass and blood lipid levels mainly causing atherosclerosis and hypertension, which further lead to cardiovascular complications. The objective of the study was to investigate the crude extract of Caralluma edulis (CE.Cr) for its potential against high-fat diet (HFD)-induced obesity and its related complications. Hyperlipidemia was induced in Wistar albino rats with HFD (1% cholesterol + 0.5% cholic acid) for 28days. Treatment groups were administered with different doses of CE.Cr (100, 300 and 500mg/Kg, p.o.) and the standard group received atorvastatin. At the end of study, sera were analyzed for biochemical markers and the aorta was dissected for microscopic examination. Antioxidant potential was evaluated and high-performance liquid chromatography (HPLC) analysis was performed. The hypotensive potential of CE.Cr was evaluated through an invasive technique. HPLC analysis of CE.Cr showed the presence of chlorogenic acid, caffeic acid, apigenin and naringenin. Histological examination of the aorta section showed anti-atherosclerotic effects which were also evident from decrease in serum total cholesterol, triglycerides and low-density lipoproteins levels. CE.Cr decreased mean arterial blood pressure and evoked significant hypotensive effects. The crude extract of C. edulis showed anti-obesity, antihypertensive, anti-atherosclerotic and antioxidant potential.

Anti-obesity effects of corn peptide on 3T3-L1 preadipocytes and C57BL/6J obese mice

ABSTRACT Corn peptide (CP) is a small, natural, biologically active peptide obtained by protease-catalysed hydrolysis of corn. CP exerts antihypertensive, hypoglycaemic, antihyperlipidemic, antioxidant, and antitumor effects, as well as prevents cardiovascular and cerebrovascular diseases. Although CP plays a role in preventing obesity-related diseases, its role in reducing obesity has not yet been determined. In this study, we analysed the inhibitory effects of CP on lipid droplet accumulation in 3T3-L1 preadipocytes and high-fat diet (HFD)-induced C57BL/6J Obese Mice. The results show that CP could inhibit preadipocyte differentiation and oil accumulation in 3T3-L1 preadipocytes. Oral CP administration reduced serum triglyceride (TG) content, epididymal fat weight, abnormal liver fat droplet accumulation, and C/EBPα expression. Furthermore, combination of CP administration and exercise reduced body, liver, and adipose tissue weights; decreased serum total cholesterol (TC), triglyceride and low-density lipoprotein (LDL) levels; and inhibited hepatic lipid droplet accumulations and epididymal fat cell hypertrophy. Additionally, this combination inhibited the expression of transcription factors, C/EBPα, C/EBPβ, and PPARγ, and adipogenic factors, FABP4 in mice. In conclusion, oral administration of CP inhibited lipid droplet accumulation and counteracted HFD-induced obesity in mice.

Amino Acid Conjugates of 2-Mercaptobenzimidazole Ameliorates High-Fat Diet-Induced Hyperlipidemia in Rats via Attenuation of HMGCR, APOB, and PCSK9

This study was designed to explore the antihyperlipidemic effects of amino acid derivatives of 2-mercaptobenzimidazole (4J and 4K) in high-fat diet (HFD)-fed rats. Male Sprague-Dawley rats were divided into nine groups which received either standard diet or HFD for 28 days. Blood samples were taken on 27th day from HFD-fed rats to ensure hyperlipidemia. HFD-induced hyperlipidemic rats later received daily dosing of either vehicle or simvastatin (SIM; 20 mg/kg) or 4J/4K compounds (10, 20, and 30 mg/kg) for 12 consecutive days. On 40th day, animals were sacrificed, and blood samples were collected for the determination of serum lipid profile and liver function parameters. Liver samples were harvested for histopathological, antioxidant, and qPCR analyses. Molecular docking of tested compounds with HMGCR was also performed to assess the binding affinities. 4J and 4K dose dependently decreased serum total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoproteins, alanine transaminase (ALT), and aspartate aminotransferase (AST) levels while significantly alleviated high-density lipoproteins. However, SIM failed to reduce AST and ALT levels. Moreover, tested compounds displayed antioxidant effects by inducing superoxide dismutase and glutathione levels. Histopathology data also displayed protective effects of 4J and 4K against HFD-induced fatty changes and hepatic damage. In addition, 4J and 4K downregulated transcript levels of HMGCR, APOB, PCSK9, and VCAM1, and molecular docking analysis also supported the experimental data. It is conceivable from this study that 4J and 4K exert their antihyperlipidemic effects by modulating multiple targets regulating lipid levels.

Lipid profile in oral potentially malignant disorders and oral squamous cell carcinoma - A prognostic view.

Lipids play an important role in the maintenance of cell integrity. Various tobacco-associated products are known to induce the generation of free radicals and reactive oxygen species, responsible for the high rate of oxidation/peroxidation of polyunsaturated fatty acids. These further release peroxide radicals, causing increased utilization of lipids leading to hypolipidemia. The aim of this study was to evaluate and compare the lipid profile pattern of patients with oral potentially malignant disorders (OPMDs) and oral squamous cell carcinoma (OSCC) with healthy controls. The study included 90 subjects with 30 OPMDs, 30 OSCC and 30 healthy controls. Fasting blood samples were collected from subjects and were analysed for serum lipids, including the following: i) Total cholesterol (TC) ii) High-density lipoproteins (HDL) iii) Low-density lipoproteins (LDL) iv) Very low-density lipoproteins (VLDL) v) Triglycerides (TG) vi) CHO/HDL ratio by using semi auto analyser. The statistical tests used were the independent t-test, ANOVA test. A P value of <0.05 and <0.01 was considered statistically significant. A statistically significant decrease in serum TC, LDL and CHO/HDL ratio was observed among OPMD and OSCC groups than controls, whereas a significant decrease in serum VLDL and TG (p value <0.01) in poorly differentiated OSCC was seen. The study shows an association between lipid variations and OPMD and OSCC. Low levels of lipids could be due to the rapidly dividing cells in premalignancies and malignancies utilizing them for new membrane biogenesis. Thus, lower lipid status may be a useful indicator for initial changes happening in neoplastic cells.

The effect of Allium hirtifolium bulb on serum lipid profile in adult patients with hyperlipidemia: A randomized double-blind placebo-controlled clinical trial

BackgroundOne of the first goals of reducing the risk of cardiovascular disease (CVD) is to achieve effective therapies for hyperlipidemia. This study aimed to investigate the effect of Allium hirtifolium bulbs on serum lipid profile in patients with hyperlipidemia. MethodsThis clinical trial was conducted on hyperlipidemic patients in two drug (Allium; n = 25) and placebo (n = 24) groups. The first group received 500 mg of A. hirtifolium bulbs twice daily for 6 weeks, while the second group received placebo for the same frequency and duration. Cholesterol, triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting blood sugar (FBS), creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured at the beginning and the end of study and were compared between the groups. ResultsA. hirtifolium reduced total cholesterol and LDL significantly compared to the placebo (P < 0.05). However, no significant effects on other parameters were observed. Furthermore, the use of A. hirtifolium had no effects on renal and liver function tests. ConclusionThe use of A. hirtifolium bulbs can decrease serum total cholesterol and LDL in hyperlipidemic adult patients.

Improvement in cardiometabolic risk markers following an oatmeal diet is associated with gut microbiota in mildly hypercholesterolemic individuals

Cardiovascular diseases have been the leading cause of death worldwide for decades. Some animal studies have indicated that oatmeal could improve gut microbiota and cardiometabolic risk markers. However, vivo evidence remained limited, especially in individuals with mild hypercholesterolemia. Our purpose was to explore the beneficial effects of oatmeal on serum lipids, oxidative stress and inflammation levels, and their correlations with gut microbiota and short-chain fatty acids (SCFAs) in mildly hypercholesterolemic individuals. The study was a randomized, single-blind, placebo-controlled trial. A total of 62 qualified participants were randomly divided into control group and oatmeal group with a 45-day follow-up. 16S rDNA and Gas-Chromatography Mass Spectrometry were employed respectively to measure the changes in gut microbiota and SCFAs at the start and the end of the intervention period. Cardiometabolic risk markers were assayed via commercial kits. The results suggested that oatmeal could significantly decrease serum total cholesterol (TC) (−8.59 %, p = 0.013), low density lipoprotein cholesterol (LDL-c) (−12.97 %, p = 0.004) and non-high density lipoprotein cholesterol (non-HDL-c) (−10.98 %, p = 0.040) level. In terms of oxidative stress, oatmeal significantly increased serum total antioxidant capacity (T-AOC) (21.98 %, p < 0.001), superoxide dismutase (SOD) (15.53 %, p = 0.044) levels and decreased concentration of malondialdehyde (MDA) (−19.11 %, p = 0.033) compared with control group. While no significant effect was observed in inflammatory factors. SCFAs results indicated that oatmeal could significantly increase serum acetic acid, propionic acid and valeric acid. The results of 16S rDNA showed that there was a significant difference in the alteration of β-diversity between groups throughout the whole trial. Oatmeal resulted in the increases of Akkermansia, Dialister, Faecalibacterium, Barnesiella, Agathobacter, Lactobacillus and the decrease of Ruminococcaceae-MK4A214-group. Correlation analysis further suggested that the lipids regulation effect of oatmeal may be mainly mediated by Lactobacillus and Dialister, as well as some SCFAs (e.g., acetic acid and propionic acid), while Barnesiella and Akkermansia may play a crucial role in ameliorating oxidative stress level. In conclusion, despite of its small sample size, the present study is the first clinical trial performed in Chinese individuals with mild hypercholesterolemia to explore the effects of oatmeal on serum lipids, oxidative stress, inflammation levels, and gut microbiota. The results demonstrated that oatmeal could induce some beneficial changes in serum lipids, oxidative stress, gut microbiota composition and SCFAs. Correlation analysis further extended our understanding of the role of gut microbiota and SCFAs in improving cardiometabolic risk markers.

Association of lipid profile with severity of hepatitis B virus related chronic liver disease in adult

Background: Chronic liver disease (CLD) is a major health problem and contributes to a common cause of hepatocellular carcinoma, disability and death worldwide. Hepatitis B virus (HBV) is the leading cause of CLD in our country. Abnormal lipid profile is expected in those with severe liver dysfunction.&#x0D; Objective: The objective of the study was to determine the alteration of lipid profile (total cholesterol, triglyceride, LDL-C and HDL-C) in HBV positive adult CLD patients and to correlate with severity of liver damage.&#x0D; Methods: This case control study was conducted for one year between January 2018 to December 2018. One hundred and three patients, &gt;18 years old, admitted with HBV positive CLD in Dhaka Medical College Hospital were recorded as case and 103 age and sex matched, healthy population, were recorded as control. A standard case record form including demographics, histories, clinical examinations and different investigations were completed for each group. Then lipid profile values of cases were compared to controls and different Child-Pugh and MELD scores, were used to see severity of liver damage in CLD patients.&#x0D; Results: In patients with HBV positive adult CLD, there were a significant decrease in serum total cholesterol. LDL-C and HDL-C levels compared to the control group (mean 131.4 vs 179.3, 72.5 vs 109.6, and 31.0 vs 40.4 mg/dl, respectively; p&lt;0.001). Comparison of lipid profile with pathologic progression of CLD revealed that these values were diminished gradually with progression of liver damage. Overall triglyceride level was decreased marginally in cases when compared to controls (mean 139.2 vs 146.6 and p=0.047) and this reduction was observed in only advanced stage.&#x0D; Conclusion: Serum total cholesterol, LDL-C and HDL-C level in HBV positive CLD patients were low and diminished gradually with severity of liver damage. Triglyceride level was marginally significant and diminished in advanced CLD.&#x0D; Bang Med J Khulna 2021; 54 : 08-12

7-aminocephalosporanic acid, a novel HSP90β inhibitor, attenuates HFD-induced hepatic steatosis

Hepatic steatosis is one of the most important causes of liver disease worldwide. Heat shock protein 90 (HSP90) is essential for numerous client proteins. Recently, more attention was focused on increased HSP90 levels in hepatic steatosis, especially HSP90β. Thus, great efforts have been made to develop HSP90β inhibitors, and most natural inhibitors are derived from microorganisms. In this study, using microarray chips and surface pasmon resonance (SPR) technology, we screened 189 antibiotics in order to obtain an inhibitor directly binding to the non-N-terminal domain of HSP90β. Finally, we discovered an antibiotic, 7-aminocephalosporanic acid (7ACA), with a KD value of 6.201 μM between 7ACA and non-N-terminal domain of HSP90β. Besides, 7ACA was predicted to interact with the middle domain (MD) of HSP90β. In HepG2 cells, we found that 7ACA reduced cellular total cholesterol (TC) and triglyceride (TG) by decreasing sterol regulatory element-binding proteins (SREBPs). In HFD fed mice, administration of 7ACA (5, 10, and 25 mg kg−1 d−1, ig, for 12 weeks) dose-dependently decreased serum TC and TG and played an important role in protecting liver and adipose tissue from lipid accumulation. In conclusion, our study demonstrated that antibiotic 7ACA, as an HSP90β middle domain inhibitor, was promising for the development of lipid-lowering drugs.

Responses of Lactation, Rumen Fermentation and Blood Biochemical Parameters with Increasing Dietary Inulin Supplementation in Mid-Lactation Dairy Cows

Effects of dietary supplementation of inulin in dairy cows were investigated in this study. Thirty-six mid-lactation Holstein dairy cows were randomly divided into six groups with six cows per group and offered a total mixed ration supplemented with 0 (control), 50, 150, 200, 250 and 350 g/d inulin per head, respectively. The animals were pre-fed for 2 weeks before rumen fluid, milk and blood samples were collected weekly for 3 weeks. With increasing inulin doses, milk yield (p &lt; 0.01) and milk fat concentration (p = 0.04) were linearly increased, while milk urea nitrogen (p &lt; 0.01) and somatic cell count (p = 0.04) were linearly decreased. Linear increases were also detected in the proportions of milk saturated fatty acids (p &lt; 0.01) and polyunsaturated fatty acids (p = 0.04); however, milk monounsaturated fatty acids were linearly decreased (p = 0.04). The ruminal concentrations of acetate, propionate and butyrate increased, while the ruminal pH and the concentration of NH3-N reduced at a decreasing rate with increasing inulin doses (p &lt; 0.01). Moreover, the concentrations of lactic acid (p = 0.03) and total volatile fatty acids (p &lt; 0.01) were linearly upregulated. There were linear increases in the serum concentrations of superoxide dismutase (p = 0.02), immunoglobin G (p &lt; 0.01), immunoglobin M (p = 0.04), interleukin-2 (p &lt; 0.01) and interleukin-10 (p = 0.04); quadratic increases in serum total protein (p &lt; 0.01) and albumin (p = 0.02) and linear decreases in serum total cholesterol (p = 0.02), triglyceride (p &lt; 0.01) and malondialdehyde (p &lt; 0.01). The results indicated that inulin increased milk production, shifted milk fatty acid profile, upregulated rumen volatile fatty acid concentration, and enhanced antioxidant and immunity function in dairy cows in a dose-dependent manner.

A systematic review and meta-analysis of cherry (Prunus spp.) consumption on glycemic markers and lipid profile

Cherry fruit (Prunus spp.) has gained growing attention in cardiometabolic health mainly due to its bioactive compounds, including anthocyanins and phenolic acids. However, the effectiveness of cherries on makers of cardiovascular health has been controversial yet. The present report aimed to summarize the effect of cherry consumption on glycemic markers and lipid profile in adults. Four databases were searched up to June 2021. Randomized controlled trials (RCTs) investigating the effects of tart or sweet cherries on glycemic markers (fasting blood glucose, fasting insulin, and HOMA-IR) and serum lipids (triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol) were included in the meta-analysis. Seven RCTs were included in the meta-analysis. Meta-analysis revealed that cherry had no significant effects on glycemic markers or lipid profile. Although, in subgroup analysis, cherry significantly decreased serum total cholesterol in subjects with a mean body mass index (BMI) ranging between 25 and 29.9 kg/m 2 (WMD: -14.40 mg/dl, 95% CI: - 27.33, - 1.48), and serum triglycerides in those with mean BMI ≥30 kg/m 2 (WMD: - 17.65 mg/dl, 95% CI: - 24.70, - 10.59). Overall, this meta-analysis showed no significant effects of cherry consumption on glycemic markers and lipid profile. • Overall, cherry had no significant effect on glycemic markers or blood lipids. • Cherry significantly decreased total cholesterol in overweight individuals. • Cherry decreased serum triglycerides significantly in obese individuals.

Inhibition of Serum Lipase as a Mechanism of Action for Anti-Obesity Potentials of Dioscorea bulbifera Extracts on Wistar Rats

Objectives: Dioscorea bulbifera possesses profound therapeutic potential and is commonly used in traditional Indian, African and Chinese medicine. The present study aimed to evaluate the effect of a hydromethanolic extract of Dioscorea bulbifera on the serum lipid profile, lipase, ghrelin, food intake and body weight of high-fat obese Wistar rats. Methods: Thirty (30) male Wistar rats weighing 200 – 250 g were used for the study. Obesity was induced using a formulated high-fat diet for six (6) weeks. They were divided into six (6) groups of five (5) rats each. The negative control received distilled water, while the positive control received a standard antihyperlipidemic drug, simvastatin. Obese rats were treated with hydromethanolic extract of Dioscorea bulbifera at 200 mg/kg and 400 mg/kg for a period of two (2) weeks. Results: The results showed significantly decreased serum total cholesterol (TC), low-density lipoprotein (LDL), lipase, fasting blood glucose and body weight of experimental animals compared to the negative control (P &lt; 0.05), while serum high-density lipoprotein (HDL) and ghrelin were found to be significantly higher in experimental animals compared to the negative control (p &lt; 0.05). There was no significant change in the food intake of the animals. Conclusion: The antiobesity potentials of hydromethanolic extracts of Dioscorea bulbifera may be attributable to their ability to reduce lipase activity while attenuating the lipid profile in high-fat obese Wistar rat models. Therefore, this study considers Dioscorea bulbifera as a potential natural anti-obesity agent with possible anti-lipase activity.

Recombinant Hirudin Protects the Vasculature and Myocardium in Atherosclerotic Rats by Inhibiting the p38 MAPK/NF-kB Signaling Pathway

Recombinant hirudin (r-hirudin) has a good anticoagulant effect and has a certain inhibitory effect on atherosclerosis (AS), however, its intrinsic mechanism of inhibiting AS is still unclear. In this study, we investigated the mechanism underlying the vascular and myocardial protective effects of r-hirudin in AS rats through animal experiments. A rat AS model was established by high-fat diet feeding combined with common carotid artery balloon injury. The model rats were given low, medium, or high doses of r-hirudin (0.05, 0.1, or 0.2 mg/kg/ day), simvastatin tablets (1 mg/kg/day) and p38 mitogen-activated protein kinase (MAPK) pathway inhibitors (SB203580, 100 mg/kg/day) by gavage for 8 weeks. The results showed that in AS rats, r-hirudin significantly alleviated pathological changes in the common carotid artery and myocardial tissue; decreased serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein-cholesterol (LDL-C) levels; increased highdensity lipoprotein-cholesterol (HDL-C) levels; decreased serum oxidized low-density lipoprotein (ox-LDL), tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and endothelin (ET)-1 levels; increased nitric oxide (NO) levels; and decreased p38 MAPK, nuclear factor-kappa B (NF-κB), caspase-9, caspase-3 mRNA and protein expression. This study showed that r-hirudin may protect blood vessels and the myocardium in AS rats by adjusting blood lipid levels and inhibiting the p38 MAPK/NF-κB signaling pathway to exert anti-inflammatory and anti-apoptotic effects and protect the vascular endothelium.

Functional Effect of Lesser Yam Symbiotic Yoghurt on Hypercholesterolemia Wistar Rats

Synbiotic lesser yam yoghurt is fermented drink made from the mixture of cow’s milk and lesser yam extract which has functional benefits. Lesser yam yoghurt contains lactic acid bacteria, lactic acid, inulin, and soluble fiber which can improve the lipid profile of hypercholesterolemia sufferers. This study aims to determine the effect of the intake of lesser yam yoghurt on the lipid profile of hypercholesterolemia wistar rats. This study used nested randomized design with two factors, the first factor was a feeding group (0,1,2,3,4 ml/day, while the second factor was the time of blood collection (0, week 1 and week 2). The data obtained were analyzed by using ANAVA and further test DMRT (Duncan Multiple Range Test) with a level of 5%. The results showed that giving lesser yam yoghurt for 2 weeks had a significant effect on the lipid profile improvement. Rats from 4 ml of yoghurt treatment experienced a decrease in total serum cholesterol by 48.4%, triglyceride levels by 35.8% and LDL levels by 65,5% and an increase in serum HDL levels by 150.3%. So it can be concluded that the intake of synbiotik lesser yam yoghurt has functional benefits in improving the lipid profile of hypercholesterolemia rats.

Ilexsaponin A1 Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice.

Bile acid (BA) metabolism is an attractive therapeutic target in nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the effect of ilexsaponin A1 (IsA), a major bioactive ingredient of Ilex, on high-fat diet (HFD)-induced NAFLD in mice with a focus on BA homeostasis. Male C57BL/6J mice were fed an HFD to induce NAFLD and were treated with IsA (120 mg/kg) for 8 weeks. The results showed that administration of IsA significantly decreased serum total cholesterol (TC), attenuated liver steatosis, and decreased total hepatic BA levels in HFD-induced NAFLD mice. IsA-treated mice showed increased BA synthesis in the alternative pathway by upregulating the gene expression levels of sterol 27-hydroxylase (CYP27A1) and cholesterol 7b-hydroxylase (CYP7B1). IsA treatment accelerated efflux and decreased uptake of BA in liver by increasing hepatic farnesoid X receptor (FXR) and bile salt export pump (BSEP) expression, and reducing Na+-taurocholic acid cotransporting polypeptide (NTCP) expression. Alterations in the gut microbiota and increased bile salt hydrolase (BSH) activity might be related to enhanced fecal BA excretion in IsA-treated mice. This study demonstrates that consumption of IsA may prevent HFD-induced NAFLD and exert cholesterol-lowering effects, possibly by regulating the gut microbiota and BA metabolism.

Hypocholesterolemic effect of designer yogurts fortified with omega fatty acids and dietary fibers in hypercholesterolemic subjects

A cohort study of 90 days was designed to explore the hypercholesterolemic associated blood pressure with intake of extruded flaxseed powder (EFSP) fortified yogurts. The hypercholesterolemic subjects were distributed into two groups (1 and 2), then blood samples and blood pressure were taken. Descriptive statistics were used for comparison between groups. A significant increase in serum total cholesterol (TC) (6.330.48 to 6.510.04 mmol/dL) and low-density lipids-cholesterol (LDL-C) (5.170.28 to 5.370.47 mmol/dL) was observed in participants consuming plain milk yogurts for 30 days. A significant decrease in TC (6.470.95 to 6.28 ± 0.84) and LDL-C (5.350.29 to 5.130.44 mmol/dL) was observed in the group consuming EFSP fortified sheep milk yogurt. Similarly, a significant decrease in serum TC (6.381.01 to 6.200.98 mmol/dL), and LDL-C (5.301.16 to 4.980.99 mmol/dL) was noticed in the group consuming EFSP fortified cow milk yogurt. The intake of fortified yogurts reduced significantly serum cholesterol associated with blood pressure in both groups.

Canned Beans Decrease Serum Total and LDL Cholesterol in Adults with Elevated LDL Cholesterol in a 4-wk Multicenter, Randomized, Crossover Study

BackgroundPractical risk reduction strategies are needed to address cardiovascular disease. Beans can decrease LDL cholesterol; however, research into different daily amounts and varieties is warranted. ObjectivesTo examine the effects of canned beans (daily rotation of black, navy, pinto, dark red kidney, white kidney) in 1-cup (1CB, 180 g) and ½-cup (½CB, 90 g) daily amounts compared with a 1-cup white rice (WR) control on serum lipid and glycemic biomarkers in adults with elevated LDL cholesterol. MethodsAdults [n = 73, mean ± SD age: 48.1 ± 14.2 y; BMI (in kg/m2): 25.9 ± 4.22; fasting serum LDL cholesterol: 3.0–5.0 mmol/L] consumed 1CB, ½CB, and WR for 4-wk treatment periods separated by ≥4-wk washouts in a multicenter, randomized, crossover study. Fasting serum LDL cholesterol (primary outcome) and other lipids and glycemic biomarkers (secondary outcomes) were measured on study days 1 and 29 of each treatment period with study day 29 values compared using repeated-measures ANCOVA, including study day 1 values as covariates. ResultsTreatment completion was n = 66 for 1CB, n = 68 for ½CB, and n = 64 for WR. Total cholesterol on study day 29 was lower for 1CB (P = 0.04) but not ½CB (P = 0.77) compared with WR (–5.46%, –2.74%, –0.65% changes from study day 1, respectively) and did not differ between 1CB and ½CB (P = 0.17). LDL cholesterol on study day 29 was also lower for 1CB (P = 0.002) but not ½CB (P = 0.30) compared with WR (–8.08%, –3.84%, +0.49% changes from study day 1, respectively) and did not differ between 1CB and ½CB (P = 0.11). Other lipids and glycemic biomarkers did not differ among treatments. ConclusionsConsumption of 1 cup (180 g) of canned beans of multiple varieties decreased total and LDL cholesterol in adults with elevated LDL cholesterol, supporting a practical strategy for cardiovascular disease risk reduction. This trial was registered at http://clinicaltrials.gov as NCT03830970.

Potential effect antidiabetic of a medicamentous receipt made up of Parquetina nigrescens (Periplocaceae) and Erythrina senegalensis (Fabaceae) and effects on the lipidic profile and the glycation of hemoglobin in rats diabetics

The medicinal recipe composed of Parquetina nigrescens (Periplocaceae) and Erythrina senegalensis (Fabaceae) is a remedy used in traditional medicine in Côte d&#39;Ivoire to treat diabetes. this study aims to assess the potential anti-diabetic effect of the drug recipe (RPNES) and its effect on the lipid profile and hemoglobin glycation in diabetic rats. Diabetes mellitus is induced by an intraperitoneal injection of streptozotocin, dissolved in a citrate buffer solution, at a dose of 65 mg/kg BW and a nicotinamide solution at a dose of 230 mg/kg BW to Wistar rats. Healthy rats and diabetic rats are treated orally with RPNES daily for 28 days and blood samples from control and treated rats are taken for assay of biochemical parameters. This study shows that RPNES, administered at doses greater than or equal to 600 mg/kg BW, causes a significant decrease in blood sugar in diabetic rats. in addition, a significant decrease in serum total cholesterol and triglyceride levels, associated with an increase in serum HDL cholesterol level, was observed in diabetic rats which received RPNES at 800 mg/kg BW, after 28 days treatment. In addition, after 90 days of treatment, RPNES (800 mg/kg BW) induces a significant decrease in the percentage of glycated hemoglobin in diabetic rats. This study also revealed that, in diabetic rats, RPNES had antihyperglycemic and antidiabetic effects similar to those of glibenclamide. RPNES is also a hypolipemic substance which corrects lipid disorders associated with diabetes, normalizes HDL cholesterol and lowers HbA1c levels in diabetic rats. These results justify the use in traditional medicine of this medicinal recipe composed of Parquetina nigrescens and Erythrina senegalensis to treat diabetes.

Hepatoprotective and Anti-Obesity Properties of Sardine By-Product Oil in Rats Fed a High-Fat Diet.

Excess lipid intake can trigger liver lipid accumulation and oxidative responses, which can lead to metabolic disturbances and contribute to hepatic steatosis and obesity and increase the risk of cardiovascular disease. Production of fish oil rich in omega-3 is a good opportunity for valorizing fish by-products in the therapeutic field. In this study, we explored the effects of oil from Sardina pilchardus by-products on cardiometabolic and oxidative disorders caused by toxic effects of excess lipids in obese rats. Three groups of obese rats received either 20% sardine by-product oil (SBy-Ob-HS; experimental group), 20% fillet oil (SF-Ob-HS; positive control group), or a high-fat diet (Ob-HS). Normal weight rats received a standard diet (normal). There was a significant decrease in serum total cholesterol (TC), triacylglycerols (TG), and insulin concentrations in the SBy-Ob-HS group compared with the SF-Ob-HS group. Compared with the Ob-HS group, TC and TG, glycemia, glycosylated hemoglobin, and insulinemia were decreased in the SBy-Ob-HS (more notably) and SF-Ob-HS groups. Furthermore, hepatic lipids, low density lipoprotein-cholesterol (C), the non-esterified cholesterol/phos-pholipids ratio, serum transaminases activities and lipid peroxidation were lower and serum high density lipoproteins-C were higher in the SBy-Ob-HS and SF-Ob-HS groups compared with the Ob-HS group. Serum isoprostane concentrations were reduced in the SBy-Ob-HS (more notably) and SF-Ob-HS groups compared with the Ob-HS and normal groups. The activities of antioxidant enzymes in tissues were enhanced, particularly in the by-product oil group. The oil extracted from by-products demonstrate anti-obesity properties (hypolipemiant, hepatoprotective, antiatherogenic, antidiabetic, and antioxidant) that may be beneficial for the management of obesity and its complications, such as hepatic steatosis.

Effect of Brain-Cor Injection of Ginkgo on the Hyperlipemia and Thrombosis: Fundamental Study

We have done this study to verify effects on the serum lipid content (TC, TG, HDL-C) in experimental model of hyperlipemia and on the blood coagulability in experimental model of thrombosis. Background: Female hormone preparation is limited in long term use because of hyperlipemia and thrombosis that are complications occurring in long term use of female hormone preparations for dysfunctional uterine bleeding, climacteric disorder, female genital organs tumor. Therefore to prevent complications such as hyperlipemia and thrombosis with female hormone preparation use are the acute problems not only for the effective treatment of gynecological diseases but also for the lowering of incidence rate of hypertension, arteriosclerosis, hyperlipemia and thrombosis. We made brain-cor injection of Ginkgo for the treatment of hyperlipemia and thrombosis that are complications occurring in long term use of female hormone preparations and verified its effects on the serum lipid content in experimental model of hyperlipemia and on the blood coagulability in experimental model of thrombosis. Objects and Materials: Wistar rats with 160~180 g in body weight were used as experimental animals, brain-cor injection of Ginkgo(70mg/20mL) made from Ginkgo extract that consists of flavonoid content above 24%, total lactone content above 6% and total ginkgolic acid content below 5μg/g was used as drugs. Methods: For 15 days brain-cor injection of Ginkgo 10mg/kg was injected in abdominal cavity of experimental model of hyperlipemia by tween-80, serum was separated from collected blood in orvita vein, serum TC (Total Cholesterol) content, serum TG (Triglyceride) content and serum HDL-C (High Density Lipoprotein-Cholesterol) content were examined with blood automatic biochemical analyzer and measurements were compared each other. For 15 days brain-cor injection of Ginkgo 10mg/kg was injected in abdominal cavity of experimental model of hyperlipemia and thromboplastin 0.5% 0.1mL/10g was injected on cauda vein in an hour after the last injection of Ginkgo. BT (Bleeding Time), CT (Clotting Time), APTT (Activated Partial Thromboplastin Time) and PT (Prothrombin Time) were examined and measurements were compared each other. Results: Brain-cor injection of Ginkgo decreased serum TC and TG content and increased serum HDL-C content in experimental model of hyperlipemia. And brain-cor injection of Ginkgo prolonged BT, CT, APTT and PT significantly in experimental model of thrombosis.